Beijing, China, August 22, 2023 – TINAVI Medical Technologies Co., Ltd. (Stock Code: 688277) released its 2023 Interim Report, providing a comprehensive overview of the company's financial performance and operational achievements during the first half of the year.
Financial Highlights:
• Operating revenue for the first half of 2023 reached approximately 820 million yuan, marking a robust year-on-year growth of 34.41%.
• Net loss attributable to shareholders of the listed company amounted to approximately -370 million yuan, demonstrating a noteworthy reduction of 16.48% compared to the same period last year.
Clinical Reach and Expansion:
• By the end of the first quarter of 2023, the clinical application of TiRobot® orthopedic robots had expanded to encompass more than 170 medical institutions across 30 provinces, autonomous regions, and municipalities.
• The surgical volume conducted using TiRobot® orthopedic robots surpassed 40,000 cases.
